Biocon Biologics partners with Sandoz for distribution of its biosimilar to treat immune-related diseases in Japan
时间:2024-06-26 09:03:52 阅读(143)
Biocon Biologics Ltd on Friday signed a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute th injection of Adalimumab BS in Japan.
“Based on this Agreement, Viatris has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024. Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate,” the company said in a statement.
“Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth,” it added.
The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
Biocon Biologics recently announced the successful completion of its integration of the acquired Viatris’ biosimilars business in 120 countries ahead of schedule, marking a significant milestone in the Company’s journey as a fully integrated, global biosimilars enterprise. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, and ophthalmology.
猜你喜欢
- Wipro, Reliance Industries, Tata Motors, Bank of Baroda, Ujjivan Small Finance Bank stocks in focus
- Yamuna Authority initiates land survey near Noida Airport; new sectors to come up with residential and commercial projects
- Year ender 2023- Aiming for the cloud
- Bonds rally, stocks drift as China boost fades
- Wipro, MOFSL among 61 NSE stocks to touch 52-week lows; 17 hit 52-week highs
- Buy Hero Motorcorp, Shriram Transport Finance shares for gains; Nifty may head to 16500 if it breaches 16300
- Budget 2023- FM Nirmala Sitharaman matches her outfit with the Bahi Khaata Tab; See Photos
- Bitcoin price may hit $60,000 this quarter – 5 reasons why
- Will Nifty reclaim 19500 or erase gains- See GIFT Nifty, FII data, crude, F&O ban, more before market opens